Pregabalin: a review of its use in fibromyalgia.

Abstract

Oral pregabalin, a calcium channel alpha(2)delta-subunit ligand with analgesic, anxiolytic and antiepileptic activity, has shown efficacy in the treatment of fibromyalgia. It has a multidimensional effect in the treatment of this complex condition, and is associated with rapid and clinically significant improvements in several outcome measures relating to core symptoms of the syndrome, including pain and sleep, in patients with long-standing fibromyalgia. Pregabalin treatment is also associated with improvements in the overall health status of these patients. The beneficial effects of pregabalin are durable in patients with an initial response to the drug. The most common adverse events associated with the drug are dizziness and somnolence, which are generally mild to moderate in intensity and are tolerated by many patients. Pregabalin is, therefore, a valuable option in the first-line treatment of patients with fibromyalgia.

• Authors: Katherine A Lyseng-Williamson, M Asif A Siddiqui
• Journal: Drugs (Drugs) Vol. 68 Issue 15 Pg. 2205-23 ( 2008) ISSN: 0012-6667 [Print] New Zealand
• PMID: 18840008 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Pregabalin
• gamma-Aminobutyric Acid

Topics

• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Clinical Trials as Topic
• Drug Interactions
• Endpoint Determination
• Fibromyalgia (drug therapy)
• Humans
• Pregabalin
• gamma-Aminobutyric Acid (administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)